Accelerator Life Science Partners Overview

  • Investor Type
  • Venture Capital

  • Status
  • Active

  • Professionals
  • 8

Professionals

  • Investments
  • 33

  • Portfolio
  • 3

  • Exits
  • 20

Exits

Accelerator Life Science Partners General Information

Company Description

Founded in 2003, Accelerator Life Science Partners is a venture capital firm based in Seattle, Washington. The firm prefers to invest in medicine and healthcare companies.

Business Details

Year Founded
2003
Investor Status
Actively Seeking New Investments
Primary Investor Type
Venture Capital
Other Investor Types
Accelerator/Incubator
Corporate Office
  • 2815 Eastlake Avenue East
  • Suite 300
  • Seattle, WA 98102
  • United States
+1 (206) 000-0000

Accelerator Life Science Partners Investments (33)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
Proniras 29-Dec-2023 Later Stage VC 00.00 Drug Discovery Generating Revenue 00000 00
Automera 27-Sep-2023 00000 00000 000.00 Drug Discovery Generating Revenue 00000 0000 00.0
KayoThera 19-Jul-2023 00000 00.00 Drug Discovery Generating Revenue 000000 00000 00.0
KayoThera 13-Jul-2023 00000 00000 000.00 Drug Discovery Generating Revenue
KayoThera 15-Mar-2022 00000 00000 000 Drug Discovery Generating Revenue
ALSP Orchid Acquisition Corp I 03-Nov-2021 00000 00000 Special Purpose Acquisition Company (SPAC) Out of Business 00000 00
Proniras 11-Jul-2019 00000 00000 00.00 Drug Discovery Generating Revenue 00000 00
ApoGen Biotechnologies 23-Aug-2018 00000 00000 0000 Drug Discovery Out of Business 00000 00
Magnolia Neurosciences 13-Aug-2018 Early Stage VC 0000 Drug Discovery Generating Revenue 00000 00
Rodeo Therapeutics 25-Jul-2017 Early Stage VC 00.00 Drug Discovery Generating Revenue
You’re viewing 10 of 33 investments. Get the full list »

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Accelerator Life Science Partners Exits (20)

Company Name Exit Date Exit Type Exit Size
ALSP Orchid Acquisition Corp I 19-Nov-2021 IPO 00000
ApoGen Biotechnologies 25-May-2021 000 00 00000000
Lodo Therapeutics 16-May-2021 000000000000000000 000.00
Rodeo Therapeutics 30-Mar-2021 000000000000000000 00000
Acylin Therapeutics 01-Jul-2020 000000000000000000
Petra Pharma 14-May-2020 000000000000000000
Coba Therapeutics 24-Feb-2020 000 00 00000000
Integrated Diagnostics 09-Jul-2018 000000000000000000
Nemean Pharma 18-Nov-2016 Out of Business
Oncofactor 01-Oct-2015 Out of Business
You’re viewing 10 of 20 exits. Get the full list »

Accelerator Life Science Partners Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.

Request a free trial

Accelerator Life Science Partners Management, Team & Partners (31)

Name Title Deals Funds Boards Office
Ian Howes Managing Director 0 0 0 Seattle, WA
Melissa Yeager JD Operating Partner Seattle, WA
Merika Koday Ph.D Principal 0 0 Seattle, WA
John Latham Ph.D Clinical & Scientific Advisor Seattle, WA
Jessica Burback Chief of Staff Seattle, WA
You’re viewing 5 of 31 team members. Get the full list »

Accelerator Life Science Partners Co-Investors (11)

Name With Exits Lead Partner Series Industry
WRF Capital 2 0 Series chart Industry bar
ARCH Venture Partners 0 0 Series chart Industry bar
BioAdvance 0 Series chart Industry bar
EDBI 0 0 Series chart Industry bar
Foundation Venture Capital Group 0 0 Series chart Industry bar
You’re viewing 5 of 11 co-investors. Get the full list »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »